|  | **CCA Result** | |  |  |
| --- | --- | --- | --- | --- |
| **Variable** | **Negative**, N = 661*1* | **Positive**, N = 60*1* | **Total** (N = 721)*1* | **p-value***2* |
| **Screening Year** |  |  |  | <0.001 |
| 2019 | 61 / 661 (9.2%) | 20 / 60 (33%) | 81 / 721 (11%) |  |
| 2020 | 57 / 661 (8.6%) | 2 / 60 (3.3%) | 59 / 721 (8.2%) |  |
| 2021 | 343 / 661 (52%) | 36 / 60 (60%) | 379 / 721 (53%) |  |
| 2022 | 195 / 661 (30%) | 2 / 60 (3.3%) | 197 / 721 (27%) |  |
| 2023 | 5 / 661 (0.8%) | 0 / 60 (0%) | 5 / 721 (0.7%) |  |
| **Age** |  |  |  | 0.42 |
| 18-31 | 317 / 661 (48%) | 32 / 60 (53%) | 349 / 721 (48%) |  |
| >31 | 344 / 661 (52%) | 28 / 60 (47%) | 372 / 721 (52%) |  |
| **sex** |  |  |  | 0.52 |
| Female | 302 / 661 (46%) | 30 / 60 (50%) | 332 / 721 (46%) |  |
| Male | 359 / 661 (54%) | 30 / 60 (50%) | 389 / 721 (54%) |  |
| **Origin** |  |  |  | 0.71 |
| <1% prevalence (non-endemic) | 230 / 646 (36%) | 17 / 57 (30%) | 247 / 703 (35%) |  |
| 1-9.9% prevalence (low) | 150 / 646 (23%) | 12 / 57 (21%) | 162 / 703 (23%) |  |
| 10-49% prevalence (moderate) | 189 / 646 (29%) | 19 / 57 (33%) | 208 / 703 (30%) |  |
| ≥50% prevalence (high) | 62 / 646 (9.6%) | 8 / 57 (14%) | 70 / 703 (10.0%) |  |
| Other Country | 15 / 646 (2.3%) | 1 / 57 (1.8%) | 16 / 703 (2.3%) |  |
| **Residence** |  |  |  | 0.22 |
| Dakar | 530 / 661 (80%) | 52 / 60 (87%) | 582 / 721 (81%) |  |
| Outside | 131 / 661 (20%) | 8 / 60 (13%) | 139 / 721 (19%) |  |
| **Alcohol Consumption** |  |  |  | >0.99 |
| Yes\_past | 18 / 631 (2.9%) | 1 / 59 (1.7%) | 19 / 690 (2.8%) |  |
| No | 613 / 631 (97%) | 58 / 59 (98%) | 671 / 690 (97%) |  |
| **AUDIT-C Score** |  |  |  | >0.99 |
| Misuse | 12 / 661 (1.8%) | 1 / 60 (1.7%) | 13 / 721 (1.8%) |  |
| Negative | 649 / 661 (98%) | 59 / 60 (98%) | 708 / 721 (98%) |  |
| **Dipstick EtG** |  |  |  | 0.023 |
| Negative | 494 / 629 (79%) | 52 / 57 (91%) | 546 / 686 (80%) |  |
| Positive | 135 / 629 (21%) | 5 / 57 (8.8%) | 140 / 686 (20%) |  |
| **Drug Consumption** |  |  |  | >0.99 |
| Yes\_now | 0 / 661 (0%) | 0 / 60 (0%) | 0 / 721 (0%) |  |
| Yes\_past | 10 / 661 (1.5%) | 1 / 60 (1.7%) | 11 / 721 (1.5%) |  |
| No | 651 / 661 (98%) | 59 / 60 (98%) | 710 / 721 (98%) |  |
| **Smoking** |  |  |  | 0.45 |
| Yes\_now | 15 / 661 (2.3%) | 0 / 60 (0%) | 15 / 721 (2.1%) |  |
| Yes\_past | 57 / 661 (8.6%) | 7 / 60 (12%) | 64 / 721 (8.9%) |  |
| No | 589 / 661 (89%) | 53 / 60 (88%) | 642 / 721 (89%) |  |
| **Hypertension** | 164 / 661 (25%) | 11 / 60 (18%) | 175 / 721 (24%) | 0.26 |
| **Diabetes** | 18 / 661 (2.7%) | 2 / 60 (3.3%) | 20 / 721 (2.8%) | 0.68 |
| **BMI** |  |  |  | 0.87 |
| Normal Weight | 378 / 655 (58%) | 35 / 60 (58%) | 413 / 715 (58%) |  |
| Underweight | 99 / 655 (15%) | 10 / 60 (17%) | 109 / 715 (15%) |  |
| Overweight | 124 / 655 (19%) | 12 / 60 (20%) | 136 / 715 (19%) |  |
| Obesity | 54 / 655 (8.2%) | 3 / 60 (5.0%) | 57 / 715 (8.0%) |  |
| **Dyslipidemia** | 274 / 661 (41%) | 20 / 60 (33%) | 294 / 721 (41%) | 0.22 |
| **Family History of Liver Disease** | 12 / 661 (1.8%) | 0 / 60 (0%) | 12 / 721 (1.7%) | 0.61 |
| **Family History of HCC** | 86 / 661 (13%) | 5 / 60 (8.3%) | 91 / 721 (13%) | 0.30 |
| **HBV viral load** |  |  |  | 0.98 |
| ≤20 IU/mL | 123 / 661 (19%) | 10 / 60 (17%) | 133 / 721 (18%) |  |
| 21-2000 IU/mL | 356 / 661 (54%) | 33 / 60 (55%) | 389 / 721 (54%) |  |
| 2001-20000 IU/mL | 123 / 661 (19%) | 11 / 60 (18%) | 134 / 721 (19%) |  |
| ≥20000 IU/mL | 59 / 661 (8.9%) | 6 / 60 (10%) | 65 / 721 (9.0%) |  |
| **qAgHBs** |  |  |  | 0.35 |
| <100 IU/mL | 54 / 661 (8.2%) | 8 / 60 (13%) | 62 / 721 (8.6%) |  |
| 100-1000 IU/mL | 85 / 661 (13%) | 6 / 60 (10%) | 91 / 721 (13%) |  |
| >1000 IU/mL | 522 / 661 (79%) | 46 / 60 (77%) | 568 / 721 (79%) |  |
| **AgHBe** |  |  |  | 0.65 |
| Negative | 646 / 661 (98%) | 58 / 60 (97%) | 704 / 721 (98%) |  |
| Positive | 15 / 661 (2.3%) | 2 / 60 (3.3%) | 17 / 721 (2.4%) |  |
| **HCV Serology** |  |  |  | >0.99 |
| Negative | 660 / 661 (100%) | 60 / 60 (100%) | 720 / 721 (100%) |  |
| Positive | 1 / 661 (0.2%) | 0 / 60 (0%) | 1 / 721 (0.1%) |  |
| **HDV Serology** |  |  |  | 0.50 |
| Negative | 653 / 660 (99%) | 58 / 59 (98%) | 711 / 719 (99%) |  |
| Positive | 7 / 660 (1.1%) | 1 / 59 (1.7%) | 8 / 719 (1.1%) |  |
| **On TDF at Baseline** | 41 / 661 (6.2%) | 2 / 60 (3.3%) | 43 / 721 (6.0%) | 0.57 |
| **ALAT** |  |  |  | >0.99 |
| ≤40 IU/L | 616 / 661 (93%) | 56 / 60 (93%) | 672 / 721 (93%) |  |
| 41-80 IU/L | 33 / 661 (5.0%) | 3 / 60 (5.0%) | 36 / 721 (5.0%) |  |
| >80 IU/L | 12 / 661 (1.8%) | 1 / 60 (1.7%) | 13 / 721 (1.8%) |  |
| **APRI Score** |  |  |  | 0.30 |
| Fibrosis | 8 / 661 (1.2%) | 0 / 60 (0%) | 8 / 721 (1.1%) |  |
| No Fibrosis | 638 / 661 (97%) | 57 / 60 (95%) | 695 / 721 (96%) |  |
| Unknown | 15 / 661 (2.3%) | 3 / 60 (5.0%) | 18 / 721 (2.5%) |  |
| **FibroScan LSM** |  |  |  | 0.14 |
| F0-1 (no or mild fibrosis) | 580 / 661 (88%) | 56 / 60 (93%) | 636 / 721 (88%) |  |
| F2–3 (significant fibrosis) | 55 / 661 (8.3%) | 1 / 60 (1.7%) | 56 / 721 (7.8%) |  |
| F4 (cirrhosis) | 26 / 661 (3.9%) | 3 / 60 (5.0%) | 29 / 721 (4.0%) |  |
| **FibroScan CAP** |  |  |  | 0.14 |
| SLD | 59 / 661 (8.9%) | 2 / 60 (3.3%) | 61 / 721 (8.5%) |  |
| Normal | 602 / 661 (91%) | 58 / 60 (97%) | 660 / 721 (92%) |  |
| **UPCR Ratio** |  |  |  | 0.041 |
| Proteinuria (>0.2 mg/mg) | 618 / 661 (93%) | 60 / 60 (100%) | 678 / 721 (94%) |  |
| Normal (<0.2 mg/mg) | 43 / 661 (6.5%) | 0 / 60 (0%) | 43 / 721 (6.0%) |  |
| **Leukocyturia (Urine Strips)** |  |  |  | 0.88 |
| Leukocyturia | 193 / 659 (29%) | 17 / 60 (28%) | 210 / 719 (29%) |  |
| Normal | 466 / 659 (71%) | 43 / 60 (72%) | 509 / 719 (71%) |  |
| **Hematuria (Urine Strips)** |  |  |  | 0.67 |
| Hematuria | 78 / 659 (12%) | 6 / 60 (10%) | 84 / 719 (12%) |  |
| Normal | 581 / 659 (88%) | 54 / 60 (90%) | 635 / 719 (88%) |  |
| **Proteinuria (Urine Strips)** |  |  |  | 0.83 |
| Proteinuria | 103 / 659 (16%) | 10 / 60 (17%) | 113 / 719 (16%) |  |
| Normal | 556 / 659 (84%) | 50 / 60 (83%) | 606 / 719 (84%) |  |
| **Traditional Medicine** |  |  |  | 0.72 |
| Plant | 222 / 661 (34%) | 18 / 60 (30%) | 240 / 721 (33%) |  |
| Oil/Powder | 2 / 661 (0.3%) | 0 / 60 (0%) | 2 / 721 (0.3%) |  |
| None | 437 / 661 (66%) | 42 / 60 (70%) | 479 / 721 (66%) |  |
| **eGFR** |  |  |  | 0.32 |
| ≥60 | 599 / 661 (91%) | 52 / 60 (87%) | 651 / 721 (90%) |  |
| 15-60 | 62 / 661 (9.4%) | 8 / 60 (13%) | 70 / 721 (9.7%) |  |
| *1*n / N (%) | | | | |
| *2*Fisher's exact test; Pearson's Chi-squared test | | | | |